ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
1541
Peringkat dalam Saham
#19253
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily... ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
Harga Saham
$0.3799409
Kapitalisasi Pasar
$159.21M
Perubahan (1 hari)
-0.34%
Perubahan (1 tahun)
-71.81%
Negara
CN
Perdagangan ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)
Kategori
Healthcare
Riwayat dividen untuk ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)
Saham ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (simbol: 1541) telah membayar total 0 dividen.
Total semua dividen (disesuaikan dengan stock split): 0.00
Imbal hasil dividen (TTM): 0
Total semua dividen (disesuaikan dengan stock split): 0.00
Imbal hasil dividen (TTM): 0
Pembayaran dividen untuk ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541) dari 2026 hingga 2026
Pembayaran dividen tahunan
| Tahun | Dividen (disesuaikan dengan stock split) | Mengubah |
|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | ||
Daftar semua pembayaran dividen
| Tahun | Dividen | Mengubah |
|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | ||
Pembayaran dividen untuk perusahaan sejenis atau pesaing
| Perusahaan | Jumlah pembayaran dividen | Negara |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
